Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-negative Early Breast Cancer
Interventions: DRUG: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer|DRUG: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
Sponsor: Peking University People's Hospital